# Neuropsyquiatric Evolution After Introduction of Raltegravir QD in Substitution of Dolutegravir: NEAR QD Study

> **NCT03732625** · PHASE4 · UNKNOWN · sponsor: **Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud** · enrollment: 50 (estimated)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Raltegravir

## Key facts

- **NCT ID:** NCT03732625
- **Lead sponsor:** Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-05
- **Primary completion:** 2020-01
- **Final completion:** 2021-01
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2019-02-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03732625

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03732625, "Neuropsyquiatric Evolution After Introduction of Raltegravir QD in Substitution of Dolutegravir: NEAR QD Study". Retrieved via AI Analytics 2026-08-17 from https://api.ai-analytics.org/clinical/NCT03732625. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*